

# TOXICOGENOMICS IN PRECLINICAL DEVELOPMENT

ERIC A. G. BLOMME, DIMITRI SEMIZAROV, AND JEFFREY F. WARING

*Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois*

## Contents

- 1 Introduction
  - 1.1 Toxicogenomics and Other Emerging Technologies in Perspective
  - 1.2 Definitions and Basics of Toxicogenomics
  - 1.3 History of Toxicogenomics
  - 1.4 Applications of Toxicogenomics
- 2 Practical and Logistic Aspects of Toxicogenomics
  - 2.1 Technical Considerations
  - 2.2 Species Considerations
  - 2.3 Toxicogenomics in *In Vitro* and *In Vivo* Studies
- 3 Toxicogenomic Reference Databases
  - 3.1 The Need for Toxicogenomic Reference Databases
  - 3.2 Design and Development of Toxicogenomic Reference Databases
  - 3.3 Existing Toxicogenomic Databases
- 4 Toxicogenomics in Drug Discovery
  - 4.1 Predictive Toxicology
  - 4.2 Development of Predictive Gene Expression Signatures
  - 4.3 Case Examples
  - 4.4 Predicting Species-Specific Toxicity
- 5 *In Vitro* Toxicogenomics
  - 5.1 Objectives of *In Vitro* Toxicogenomics
  - 5.2 Proof-of-Concept Using Primary Rat Hepatocytes
  - 5.3 Use of Gene Expression Profiling to Assess Genotoxicity
  - 5.4 Current and Future Use of *In Vitro* Toxicogenomics
- 6 Toxicogenomics in Mechanistic Toxicology
  - 6.1 Objectives of Mechanistic Toxicology
  - 6.2 Case Examples of Mechanistic Toxicology